Core Viewpoint - Organovo Holdings, Inc. will rebrand as VivoSim Labs, Inc. and will begin trading under the new ticker symbol "VIVS" on April 24, 2025 [1]. Group 1 - The name change to VivoSim Labs, Inc. will be effective on April 24, 2025 [1]. - The company's common stock will continue to be listed on the Nasdaq Capital Market [2]. - Existing stockholders do not need to take any action regarding the name and ticker symbol change [2].

Core Viewpoint - Organovo Holdings, Inc. reported preliminary unaudited cash and net cash utilization results for the fiscal year ending March 31, 2025, indicating a cash balance of approximately $11.3 million and net cash utilization of $2.0 - $2.2 million for the fourth quarter [1][2]. Financial Summary - The preliminary cash and cash equivalents balance as of March 31, 2025, was approximately $11.3 million [2]. - The net cash utilization during the fourth quarter from January 1, 2025, to March 31, 2025, was approximately $2.0 - $2.2 million [2]. Nasdaq Compliance Update - The company expects to meet all requirements for continued listing on the Nasdaq Capital Market, having closed above the $1.00 minimum bid price since March 21, 2025 [3]. - Nasdaq requires a minimum of 10 consecutive trading days where the stock closes at a minimum bid price of $1.00, which the company has achieved [3]. Future Milestone Payments - The company anticipates receiving a $5 million milestone payment within the next 12 months related to the start of a Phase 2 clinical trial for the FXR agonist recently sold [4]. - Future milestone payments associated with the FXR agonist could total up to $50 million, including the $5 million payment upon the commencement of the Phase 2 clinical trial [4]. Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs effective in three-dimensional (3D) human tissues for drug development [5]. - The company utilizes proprietary technology to create 3D human tissues that replicate key aspects of native human tissue composition, architecture, function, and disease [5].

Core Insights - Organovo Holdings, Inc. is a clinical stage biotechnology company focused on developing novel treatment approaches for inflammatory bowel disease (IBD) [1] Group 1: Business Update - The company has completed the sale of its FXR Program to Lilly, receiving upfront payments and anticipating future milestone payments [2] - Organovo expects a decrease in expenditures in the coming year due to the elimination of costs associated with the FXR314 program, allowing for a more efficient use of existing capital [2] - The company plans to report its full year financials for the fiscal year ended March 31, 2025, around June 6-10, 2025 [2] Group 2: Research and Development - Organovo utilizes 3D human cellular models of Crohn's disease and ulcerative colitis to evaluate therapeutic opportunities, believing these models increase the likelihood of success in clinical trials [3] - In 2024, FXR314 showed strong performance in improving epithelial barrier function and fibrotic activity in ulcerative colitis models, as presented at the Crohn's and Colitis Congress [3] - FXR314 demonstrated synergistic benefits when paired with an approved Janus kinase (JAK) inhibitor, indicating potential for combination therapies [3] Group 3: Company Overview - Organovo is developing drugs that are effective in 3D human tissues, utilizing proprietary technology to create tissues that mimic native human tissue characteristics [4]

Core Insights - Organovo Holdings, Inc. has successfully closed the sale of its FXR program, including the lead asset FXR314, to Eli Lilly and Company on March 25, 2025 [1][2] Group 1: Transaction Details - Organovo will receive an upfront payment and future milestone payments as FXR314 achieves key regulatory and commercial milestones [2] - Eli Lilly is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development and will handle all future clinical development [2] Group 2: Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs that are effective in three-dimensional (3D) human tissues [3] - The company utilizes proprietary technology to create 3D human tissues that replicate essential aspects of native human tissue composition, architecture, function, and disease [3]

Core Viewpoint - Matinas BioPharma Holdings, Inc. has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025, while Matthew Wikler and Natasha Giordano have stepped down from the Board [1][2] Group 1: Board Appointments - Keith Murphy and Edward Neugeboren bring extensive biotech industry experience to Matinas BioPharma's Board, which is expected to enhance the company's strategic direction and shareholder value [2] - Mr. Murphy will chair the Nominating and Governance Committee and join the Compensation Committee, while Mr. Neugeboren will chair the Compensation Committee and join the Audit Committee [2] Group 2: Profiles of New Board Members - Keith Murphy has a strong background in biotech, having co-founded Viscient Bio and previously led Organovo Holdings, with significant experience at Amgen, where he was involved in the development of denosumab, generating over $6 billion in annual sales [3][4] - Edward Neugeboren has over 33 years of experience in healthcare, including roles in corporate management and investment banking, and currently serves as Chief Strategy Officer at Cronus Pharma, leading various commercial operations [5][6][7] Group 3: Company Overview - Matinas BioPharma focuses on innovative therapies utilizing its lipid nanocrystal (LNC) platform technology [8] - The company's MAT2203 is a potential oral treatment for invasive fungal infections, designed to overcome limitations of existing therapies, and has shown promising results in Phase 2 studies [9]